ATNM:NYE-Actinium Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 5.57

Change

-0.35 (-5.91)%

Market Cap

USD 0.14B

Volume

0.18M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Actinium Pharmaceuticals Inc (ATNM) Stock Analysis:
Based on the Actinium Pharmaceuticals Inc stock forecasts from 0 analysts, the average analyst target price for Actinium Pharmaceuticals Inc is not available over the next 12 months. Actinium Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Actinium Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Actinium Pharmaceuticals Inc’s stock price was USD 5.57. Actinium Pharmaceuticals Inc’s stock price has changed by -10.16% over the past week, -18.80% over the past month and -26.13% over the last year.

No recent analyst target price found for Actinium Pharmaceuticals Inc
No recent average analyst rating found for Actinium Pharmaceuticals Inc

About

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Io ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

+0.14 (+0.13%)

USD244.30B 35.26 3.60
BHVN Biohaven Pharmaceutical Holdin..

-0.40 (-0.28%)

USD10.16B N/A N/A
DNA Ginkgo Bioworks Holdings

-0.10 (-3.73%)

USD4.64B N/A N/A
RCUS Arcus Biosciences Inc

-1.13 (-5.92%)

USD1.51B 24.76 3.36
MYOV Myovant Sciences Ltd

-0.60 (-5.81%)

USD1.00B N/A N/A
ADCT ADC Therapeutics SA

-0.46 (-6.13%)

USD0.58B -99,999.99 N/A
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
ZYME Zymeworks Inc

-0.32 (-5.22%)

USD0.35B 300.20 N/A
LCTX Lineage Cell Therapeutics Inc

N/A

USD0.21B 3.63 N/A
AMAM Ambrx Biopharma Inc.

-0.08 (-1.92%)

USD0.16B N/A 0.13

ETFs Containing ATNM

Symbol Name Weight Mer Price(Change) Market Cap
RJZ ELEMENTS Linked to the Ro.. 0.00 % 0.75 %

-0.10 (-0.86%)

USD6.38M

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -7.32% 87% B+ 66% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.32% 87% B+ 63% D
Trailing 12 Months  
Capital Gain -24.42% 85% B 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.42% 85% B 21% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.58% 44% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.58% 44% F 32% F
Risk Return Profile  
Volatility (Standard Deviation) 35.89% 70% C- 30% F
Risk Adjusted Return 9.98% 44% F 22% F
Market Capitalization 0.14B 63% D 22% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.10 47% F 39% F
Price / Cash Flow Ratio -6.75 80% B- 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -35.23% 78% C+ 7% F
Return on Invested Capital -37.02% 80% B- 5% F
Return on Assets -20.68% 67% D+ 2% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.44 93% A 81% B-
Short Percent 4.19% 47% F 46% F
Beta 0.31 81% B- 89% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.